Ceribell beats Q4 revenue expectations

CeriBell

24/02/2026 21:48

Overview

Medical technology firm's Q4 revenue rose 34%, beating analyst expectations

Company reported narrower than expected Q4 adjusted loss per share and net loss

Company received FDA clearances for new neurological monitoring solutions

Outlook

Ceribell expects full-year 2026 revenue between $111 mln and $115 mln

Result Drivers

ACCOUNT EXPANSION - Revenue growth in Q4 2025 was driven by expansion into new accounts and increased adoption within existing accounts

OPERATING EXPENSES - Increased to $36.2 mln from $29.1 mln due to investments in commercial organization and headcount

Company press release: ID:nGNX1KmgqT

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$24.78 mln
$23.94 mln (8 Analysts)
Q4 EPS
Beat
-$0.36
-$0.41 (8 Analysts)
Q4 Net Income
Beat
-$13.52 mln
-$15.28 mln (7 Analysts)
Q4 Gross Profit
$21.60 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for Ceribell Inc is $29.00, about 45.1% above its February 23 closing price of $19.99

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)